TransThera Sciences (Nanjing) Inc

TransThera Sciences maintains a strong liquidity position, with cash and equivalents amounting to CNY 415.41 million, representing 76% of total assets. The company's price-to-book ratio of 45.05 indicates a high valuation relative to its book value, while the price-to-tangible-book ratio is identical, suggesting no intangible asset discounting. The company's debt-to-equity ratio is 0.0, reflecting a debt-free capital structure. The company's profitability metrics are negative, with a return on equity of -7.11% and a return on assets of -5.42%, both significantly below the industry median for biotechnology firms. The net loss of CNY 295.96 million and operating loss of CNY 295.84 million highlight the company's current unprofitability. These figures suggest the company is in an early-stage or R&D-intensive phase, typical for biotechnology firms. TransThera Sciences does not disclose segment or geographic revenue breakdowns in the latest financial data, making it difficult to assess revenue concentration or geographic exposure. The absence of segment data limits the ability to evaluate the performance of individual therapeutic areas or geographic markets. The company's growth trajectory is not clearly defined in the current financial data, as revenue is reported at CNY 0.00. The outlook for the current fiscal year does not provide numeric deltas or directional guidance, indicating a lack of near-term revenue visibility. The absence of revenue history further complicates the assessment of growth potential. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's dilution potential is also low, as shares outstanding for both basic and diluted scenarios are identical at 404.08 million. No adjustments were applied to the valuation metrics, suggesting the data is clean and unadjusted. Recent events or filings are not disclosed in the available data, and no transcripts or material announcements are referenced in the source documents. The company's financial disclosures are limited to the latest financial snapshot, with no additional commentary or strategic updates provided.